296 related articles for article (PubMed ID: 15249202)
1. Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness.
Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
Biochem Biophys Res Commun; 2004 Aug; 320(4):1096-102. PubMed ID: 15249202
[TBL] [Abstract][Full Text] [Related]
2. Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation.
Miao H; Burnett E; Kinch M; Simon E; Wang B
Nat Cell Biol; 2000 Feb; 2(2):62-9. PubMed ID: 10655584
[TBL] [Abstract][Full Text] [Related]
3. EphrinA1-induced cytoskeletal re-organization requires FAK and p130(cas).
Carter N; Nakamoto T; Hirai H; Hunter T
Nat Cell Biol; 2002 Aug; 4(8):565-73. PubMed ID: 12134157
[TBL] [Abstract][Full Text] [Related]
4. Ephrin-A1 is a negative regulator in glioma through down-regulation of EphA2 and FAK.
Liu DP; Wang Y; Koeffler HP; Xie D
Int J Oncol; 2007 Apr; 30(4):865-71. PubMed ID: 17332925
[TBL] [Abstract][Full Text] [Related]
5. EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation.
Brantley-Sieders DM; Caughron J; Hicks D; Pozzi A; Ruiz JC; Chen J
J Cell Sci; 2004 Apr; 117(Pt 10):2037-49. PubMed ID: 15054110
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of EphA2 during in vivo and in vitro renal ischemia-reperfusion injury: role of Src kinases.
Baldwin C; Chen ZW; Bedirian A; Yokota N; Nasr SH; Rabb H; Lemay S
Am J Physiol Renal Physiol; 2006 Nov; 291(5):F960-71. PubMed ID: 16735461
[TBL] [Abstract][Full Text] [Related]
7. Activation of erythropoietin-producing hepatocellular receptor A2 attenuates cell adhesion of human fallopian tube epithelial cells via focal adhesion kinase dephosphorylation.
Yang XY; Zhu WJ; Jiang H
Mol Cell Biochem; 2012 Feb; 361(1-2):259-65. PubMed ID: 22009484
[TBL] [Abstract][Full Text] [Related]
8. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.
Cheng N; Brantley DM; Liu H; Lin Q; Enriquez M; Gale N; Yancopoulos G; Cerretti DP; Daniel TO; Chen J
Mol Cancer Res; 2002 Nov; 1(1):2-11. PubMed ID: 12496364
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of EphA2 promotes tight junction formation and impairs angiogenesis in brain endothelial cells.
Zhou N; Zhao WD; Liu DX; Liang Y; Fang WG; Li B; Chen YH
Microvasc Res; 2011 Sep; 82(2):113-21. PubMed ID: 21726568
[TBL] [Abstract][Full Text] [Related]
10. A conditional feedback loop regulates Ras activity through EphA2.
Macrae M; Neve RM; Rodriguez-Viciana P; Haqq C; Yeh J; Chen C; Gray JW; McCormick F
Cancer Cell; 2005 Aug; 8(2):111-8. PubMed ID: 16098464
[TBL] [Abstract][Full Text] [Related]
11. Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression.
Brantley-Sieders DM; Fang WB; Hicks DJ; Zhuang G; Shyr Y; Chen J
FASEB J; 2005 Nov; 19(13):1884-6. PubMed ID: 16166198
[TBL] [Abstract][Full Text] [Related]
12. C1GALT1 is associated with poor survival and promotes soluble Ephrin A1-mediated cell migration through activation of EPHA2 in gastric cancer.
Lee PC; Chen ST; Kuo TC; Lin TC; Lin MC; Huang J; Hung JS; Hsu CL; Juan HF; Lee PH; Huang MC
Oncogene; 2020 Mar; 39(13):2724-2740. PubMed ID: 32005975
[TBL] [Abstract][Full Text] [Related]
13. EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma.
Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
Oncogene; 2004 Feb; 23(7):1448-56. PubMed ID: 14973554
[TBL] [Abstract][Full Text] [Related]
14. Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer.
Gökmen-Polar Y; Toroni RA; Hocevar BA; Badve S; Zhao Q; Shen C; Bruckheimer E; Kinch MS; Miller KD
Breast Cancer Res Treat; 2011 Jun; 127(2):375-84. PubMed ID: 20602165
[TBL] [Abstract][Full Text] [Related]
15. Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice.
Brantley-Sieders DM; Fang WB; Hwang Y; Hicks D; Chen J
Cancer Res; 2006 Nov; 66(21):10315-24. PubMed ID: 17079451
[TBL] [Abstract][Full Text] [Related]
16. EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma.
Miyazaki T; Kato H; Fukuchi M; Nakajima M; Kuwano H
Int J Cancer; 2003 Feb; 103(5):657-63. PubMed ID: 12494475
[TBL] [Abstract][Full Text] [Related]
17. Perturbation of the EphA2-EphrinA1 system in human prostate cancer cells by colonic (poly)phenol catabolites.
Tognolini M; Giorgio C; Hassan Mohamed I; Barocelli E; Calani L; Reynaud E; Dangles O; Borges G; Crozier A; Brighenti F; Del Rio D
J Agric Food Chem; 2012 Sep; 60(36):8877-84. PubMed ID: 22409255
[TBL] [Abstract][Full Text] [Related]
18. EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells.
Cuyàs E; Queralt B; Martin-Castillo B; Bosch-Barrera J; Menendez JA
Oncol Rep; 2017 Jul; 38(1):263-270. PubMed ID: 28560458
[TBL] [Abstract][Full Text] [Related]
19. Cell adhesion and EGFR activation regulate EphA2 expression in cancer.
Larsen AB; Stockhausen MT; Poulsen HS
Cell Signal; 2010 Apr; 22(4):636-44. PubMed ID: 19948216
[TBL] [Abstract][Full Text] [Related]
20. Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder.
Abraham S; Knapp DW; Cheng L; Snyder PW; Mittal SK; Bangari DS; Kinch M; Wu L; Dhariwal J; Mohammed SI
Clin Cancer Res; 2006 Jan; 12(2):353-60. PubMed ID: 16428472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
